their filing was specific to "Omeros" it shoes 2.5mil shares as of 12/31/15, they where holding 1.5mil shares as of Sept 2015.
they held 1.5 mil shares as of Sept 2015, new filing now shows they hold 2.5 mil shares.
January 19, 2016 2:31 PM
U.S. Vice President Joe Biden said Tuesday that the United States would speed up the approval of promising new drug combinations in his government's newly announced drive to cure cancer "once and for all."
Biden, who lost his son Beau, 46, to brain cancer last year, set out his plans at a World Economic Forum meeting of international cancer experts in Davos, a week after being appointed to lead the initiative by President Barack Obama.
So-called combination therapy is increasingly seen as central to fighting tumors, as scientists unlock the different genetic factors driving cancer cell growth, but bringing such cocktails to market can be slow and costly.
Sep 27th, 2012
Terrible decision by me to spend the money to have lasik surgery with this guy. after I found out that my vision was not corrected enough, he told me that it would cost me an additional $4000 to redo my eyes because it was outside his "1 year" free enhancement period.
THE VALUE OF USING FDA-APPROVED PRODUCTS IN THE FACILITY
By Robert B. Nelson, PA-C
Anything we can do at our facility to ensure compliance with
good standards and practices is good for business—but more
importantly, it’s good for patient care.
When we consider incorporating new technology, devices, and
pharmaceutical products in our facility, we try and gather as much information
as possible so that we can make an informed decision about its merits. When
several of our surgeons recently approached our facility’s leadership about adding
OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% to the formulary,
the fact that it had already gained approval from the US Food and Drug
Administration and that it is manufactured to meet rigorous regulatory and
manufacturing standards served as very important factors in our deliberations.
As in most centers, in the past our surgeons have used unapproved compounded
products or have used approved products in an off-label fashion for
the prevention of intraoperative miosis. Although largely successful in doing so,
compounded pharmaceuticals do carry risks, both in terms of the supply chain
and for patients’ safety. In my opinion, anytime an FDA-approved medication
can be used in place of a compounded agent, you have mitigated against risk,
you have provided the patient with a product with proven safety and efficacy,
and you have lowered your risk of criticism in the event of an untoward clinical
We were very early adopters of OMIDRIA because several surgeons in our
facility were interested in replacing the use of compounded and off-label products
in their surgical protocols. Over the 4 to 5 months we have had OMIDRIA
available at our facility, our experience has been very good. Our surgeons are
pleased with its efficacy and have the comfort of knowing that it is an FDAapproved
medication which is manufactured to rigorous FDA standards.
Another factor that appealed to us about OMIDRIA is that it has gained